$0.2310
-0.0083-3.47%
Last update: Oct 16, 7:58 PM
$0.2421
0.00281.17%

TScan Therapeutics (TCRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.22 | $-0.18 | $-0.27 | $-0.34 |
| Actual | $-0.23 | $-0.22 | $-0.18 | $-0.28 |
| Surprise | -4.55% | -22.2% | +33.3% | +17.6% |
| Revenue | ||||
| Estimate | $2.5M | $2.5M | $3.1M | $2.5M |
| Actual | $1.1M | $982000 | $2.6M | $2.5M |
| Surprise | -58.8% | -60.2% | -16.8% | +1.74% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.18 | $-0.15 | $-0.16 | $-0.12 |
| Revenue | ||||
| Consensus | $471500 | $425000 | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.23 | $-0.22 | -4.55 % |
| Q1 | May 6, 2026 | $-0.22 | $-0.18 | -22.2 % |
| Q4 | Mar 4, 2026 | $-0.18 | $-0.27 | 33.3 % |
| Q3 | Nov 12, 2025 | $-0.28 | $-0.34 | 17.6 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $1.05M | $2.55M | -58.8 % |
| Q1 | May 6, 2026 | $982.00K | $2.47M | -60.2 % |
| Q4 | Mar 4, 2026 | $2.57M | $3.09M | -16.8 % |
| Q3 | Nov 12, 2025 | $2.51M | $2.47M | 1.74 % |